HC Wainwright Has Lowered Expectations for Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Price

Mirum Pharmaceuticals (NASDAQ:MIRM) had its price target reduced by stock analysts at HC Wainwright from $185.00 to $140.00 in a report released on Thursday, MarketBeat Ratings reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective would suggest a potential upside of 32.34% from the stock’s previous close.

A number of other research analysts have also weighed in on the company. Citigroup reissued an “outperform” rating on shares of Mirum Pharmaceuticals in a report on Thursday. Citizens Jmp lifted their target price on Mirum Pharmaceuticals from $140.00 to $146.00 and gave the stock a “market outperform” rating in a report on Monday, June 15th. JPMorgan Chase & Co. upped their target price on Mirum Pharmaceuticals from $115.00 to $125.00 and gave the company an “overweight” rating in a research report on Thursday, July 2nd. Raymond James Financial reiterated a “strong-buy” rating and issued a $165.00 price target on shares of Mirum Pharmaceuticals in a report on Thursday, May 7th. Finally, Stifel Nicolaus set a $136.00 price target on shares of Mirum Pharmaceuticals in a research report on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $140.40.

Mirum Pharmaceuticals Price Performance

Shares of MIRM opened at $105.79 on Thursday. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.09 and a quick ratio of 1.99. The company’s fifty day moving average price is $110.46 and its 200-day moving average price is $101.77. Mirum Pharmaceuticals has a 1-year low of $50.25 and a 1-year high of $130.00. The firm has a market capitalization of $6.45 billion, a PE ratio of -7.77 and a beta of 0.52.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Wednesday, August 5th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.32). Mirum Pharmaceuticals had a negative return on equity of 11.28% and a negative net margin of 140.24%.The firm had revenue of $176.24 million during the quarter, compared to analysts’ expectations of $166.33 million. During the same quarter last year, the business earned ($0.12) EPS. The business’s revenue was up 37.9% on a year-over-year basis. On average, equities research analysts predict that Mirum Pharmaceuticals will post -2.01 EPS for the current year.

Insider Buying and Selling at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 2,721 shares of Mirum Pharmaceuticals stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $120.00, for a total transaction of $326,520.00. Following the completion of the transaction, the senior vice president owned 3,114 shares in the company, valued at approximately $373,680. This trade represents a 46.63% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher Peetz sold 30,000 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $95.84, for a total value of $2,875,200.00. Following the completion of the transaction, the chief executive officer directly owned 194,309 shares of the company’s stock, valued at approximately $18,622,574.56. This trade represents a 13.37% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 67,155 shares of company stock worth $7,185,662. Insiders own 8.32% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Handelsbanken Fonder AB grew its stake in shares of Mirum Pharmaceuticals by 1.6% during the 2nd quarter. Handelsbanken Fonder AB now owns 197,179 shares of the company’s stock worth $23,084,000 after purchasing an additional 3,179 shares during the period. Contravisory Investment Management Inc. boosted its holdings in Mirum Pharmaceuticals by 2.3% during the second quarter. Contravisory Investment Management Inc. now owns 4,604 shares of the company’s stock worth $539,000 after buying an additional 103 shares in the last quarter. Glenmede Trust Co. NA grew its position in Mirum Pharmaceuticals by 66.9% during the first quarter. Glenmede Trust Co. NA now owns 5,532 shares of the company’s stock valued at $511,000 after buying an additional 2,217 shares during the period. Janus Henderson Group PLC increased its holdings in Mirum Pharmaceuticals by 14.5% in the first quarter. Janus Henderson Group PLC now owns 6,945,813 shares of the company’s stock valued at $641,764,000 after buying an additional 880,505 shares in the last quarter. Finally, ADAR1 Capital Management LLC purchased a new position in Mirum Pharmaceuticals in the first quarter valued at $573,000.

Key Stories Impacting Mirum Pharmaceuticals

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Mirum reported second-quarter revenue of $176.24 million, up 37.9% year over year and above the $166.33 million consensus estimate. The company also raised or reaffirmed full-year 2026 revenue guidance at $680 million-$700 million, ahead of Wall Street’s $675.1 million estimate. Mirum Pharmaceuticals Q2 earnings report
• Positive Sentiment: Analyst sentiment remains broadly favorable, with a consensus “Moderate Buy” rating and an average price target of $143.40, well above the recent trading level. Morgan Stanley previously raised its target to $150 and maintained an overweight rating. Mirum Pharmaceuticals analyst ratings
• Neutral Sentiment: The Q2 earnings call transcript provides additional management commentary for investors, but the supplied reports do not identify a specific new catalyst or change in the company’s development and commercialization outlook. Mirum Pharmaceuticals Q2 2026 earnings call transcript
• Negative Sentiment: Mirum posted a quarterly loss of approximately $0.80 per share on an adjusted basis, narrowly missing the $0.77 consensus estimate; the reported $1.06 per-share loss under another earnings measure was also below expectations. The loss widened from $0.12 per share a year earlier, highlighting continued profitability pressure. Mirum Pharmaceuticals Q2 loss report
• Negative Sentiment: Senior Vice President Jolanda Howe sold 1,840 shares worth $193,733.60, reducing her direct holdings by 59.09%. Because the transaction was made under a pre-arranged Rule 10b5-1 plan, it may be less concerning than discretionary selling, but it nevertheless adds modest selling pressure. Mirum Pharmaceuticals insider sale

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.